Close
Novotech
Jabsco PureFlo 21 Single Use

RAUMEDIC and Sartorius Stedim Biotech Sign Partnership Agreement

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Neurocrine Nears $2.5bn Soleno Therapeutics Acquisition

Neurocrine Biosciences is close to securing a more than...

Biogen to Acquire Apellis for $5.6 Billion in Major Deal

Biogen Inc. has agreed to acquire Apellis Pharmaceuticals Inc....

Trump Announces 100% US Pharma Tariffs for Patented Drugs

The US pharma tariffs policy has been formalised through...
- Advertisement -

Sartorius Stedim Biotech (SSB), an international leading pharma and biotech supplier, and RAUMEDIC, a leading worldwide OEM manufacturer of medical- and pharmaceutical-grade polymer components and systems, announced the signing of a global partnership agreement.

This covers arrangements concerning the mutual development of innovative fluid systems and marketing of single-use tubing, which RAUMEDIC produces for and will supply to Sartorius Stedim Biotech on a long-term basis.

Sartorius Stedim Biotech will be combining its designing, manufacturing and validation expertise in single-use systems for biopharmaceutical applications with RAUMEDIC proficiency in the development and manufacture of tubing for medical and biopharmaceutical use. The alliance will provide innovative, high-quality and reliable fluid handling systems to biopharmaceutical manufacturers. Through this strategic partnership with RAUMEDIC, Sartorius Stedim Biotech will substantially expand its product and service portfolio in the area of liquid transfer technologies.

Latest stories

Related stories

Neurocrine Nears $2.5bn Soleno Therapeutics Acquisition

Neurocrine Biosciences is close to securing a more than...

Biogen to Acquire Apellis for $5.6 Billion in Major Deal

Biogen Inc. has agreed to acquire Apellis Pharmaceuticals Inc....

Trump Announces 100% US Pharma Tariffs for Patented Drugs

The US pharma tariffs policy has been formalised through...

Biomaterials and Local Drug Delivery in Implant Surgery

Advances in biomaterials and localized drug delivery systems are...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »